Serum lipids, apolipoproteins, and mortality among coronary artery disease patients

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Ding, Ding ^a,b   Li, Xinrui ^a   Qiu, Jian ^c   Li, Rui ^c   Zhang, Yuan ^c   Su, Dongfang ^a   Li, Zhongxia ^a   Wang, Min ^a   Lv, Xiaofei ^a   Wang, Dongliang ^a   Yang, Yan ^a   Xia, Min ^a   Li, Dan ^a   Hu, Gang ^b   Ling, Wenhua ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^c GUANGZHOU GENERAL HOSPITAL OF GUANGZHOU MILITARY COMMAND   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; APOLIPOPROTEIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CHINESE; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DEATH; FEMALE; FOLLOW UP; HUMAN; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROSPECTIVE STUDY; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CHINA; EPIDEMIOLOGY; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; APOLIPOPROTEIN A-I; APOLIPOPROTEINS; APOLIPOPROTEINS B; CHINA; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME;

EID: 84902257342     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/709756     Document Type: Article

References (43)

1. Yusuf S., Reddy S., Ôunpuu S., Anand S., Global burden of cardiovascular diseases-part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 2001 104 22 2746 2753 2-s2.0-0035960630
2. World Health Organization, Global Health Observatory (GHO): Raised Cholesterol 2014. http://apps.who.int/gho/data/node.main.A884
3. Pekkanen J., Linn S., Heiss G., Suchindran C. M., Leon A., Rifkind B. M., Tyroler H. A., Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. The New England Journal of Medicine 1990 322 24 1700 1707 2-s2.0-0025376017
4. Castelli W. P., Anderson K., Wilson P. W. F., Levy D., Lipids and risk of coronary heart disease. The Framingham study. Annals of Epidemiology 1992 2 1-2 23 28 2-s2.0-0026558610
5. Grundy S. M., Cleeman J. I., Merz C. N. B., Brewer H. B. Jr., Clark L. T., Hunninghake D. B., Pasternak R. C., Smith S. C. Jr., Stone N. J., Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation 2004 110 2 227 239 2-s2.0-3142729178 10.1161/01.CIR.0000133317.49796.0E
6. Castelli W. P., Garrison R. J., Wilson P. W. F., Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham study. The Journal of the American Medical Association 1986 256 20 2835 2838 2-s2.0-0023029454
7. Hu G., Cui Y., Jousilahti P., Sundvall J., Girman C. J., Antikainen R., Laatikainen T., Tuomilehto J., Joint effect of high-density lipoprotein cholesterol and low-density lipoprotein cholesterol on the risk of coronary heart disease. European Journal of Preventive Cardiology 2013 20 1 89 97 2-s2.0-84873892171 10.1177/1741826711428242
8. Cooney M. T., Dudina A., de Bacquer D., Wilhelmsen L., Sans S., Menotti A., de Backer G., Jousilahti P., Keil U., Thomsen T., Whincup P., Graham I. M., HDL cholesterol protects against cardiovascular disease in both genders, at all ages and at all levels of risk. Atherosclerosis 2009 206 2 611 616 2-s2.0-70349277844 10.1016/j.atherosclerosis.2009.02.041
9. Barter P. J., Nicholls S., Rye K., Anantharamaiah G. M., Navab M., Fogelman A. M., Antiinflammatory properties of HDL. Circulation Research 2004 95 8 764 772 2-s2.0-6344253356 10.1161/01.RES.0000146094.59640.13
10. Benn M., Nordestgaard B. G., Jensen G. B., Tybjærg-Hansen A., Improving prediction of ischemic cardiovascular disease in the general population using apolipoprotein B: the Copenhagen City heart study. Arteriosclerosis, Thrombosis, and Vascular Biology 2007 27 3 661 670 2-s2.0-33847055477 10.1161/01.ATV.0000255580.73689.8e
11. Ridker P. M., Rifai N., Cook N. R., Bradwin G., Buring J. E., Non-HDL cholesterol, apolipoproteins A-I and B 100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. The Journal of the American Medical Association 2005 294 3 326 333 2-s2.0-22244446183 10.1001/jama.294.3.326
12. Walldius G., Jungner I., Holme I., Aastveit A. H., Kolar W., Steiner E., High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. The Lancet 2001 358 9298 2026 2033 2-s2.0-0035894648 10.1016/S0140-6736(01)07098-2
13. Ansell B. J., Navab M., Hama S., Kamranpour N., Fonarow G., Hough G., Rahmani S., Mottahedeh R., Dave R., Reddy S. T., Fogelman A. M., Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003 108 22 2751 2756 2-s2.0-10744224101 10.1161/01.CIR.0000103624.14436.4B
14. Besler C., Heinrich K., Rohrer L., Doerries C., Riwanto M., Shih D. M., Chroni A., Yonekawa K., Stein S., Schaefer N., Mueller M., Akhmedov A., Daniil G., Manes C., Templin C., Wyss C., Maier W., Tanner F. C., Matter C. M., Corti R., Furlong C., Lusis A. J., von Eckardstein A., Fogelman A. M., Lüscher T. F., Landmesser U., Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. Journal of Clinical Investigation 2011 121 7 2693 2708 2-s2.0-79959919890 10.1172/JCI42946
15. Shao B., Oda M. N., Oram J. F., Heinecke J. W., Myeloperoxidase: an inflammatory enzyme for generating dysfunctional high density lipoprotein. Current Opinion in Cardiology 2006 21 4 322 328 2-s2.0-33748157807 10.1097/01.hco.0000231402.87232.aa
16. Tao S. C., Huang Z. D., Wu X. G., Zhou B., Xiao Z., Hao J., Li Y., Cen R., Rao X., CHD and its risk factors in the People's Republic of China. International Journal of Epidemiology 1989 18 supplement 1 S159 S163 2-s2.0-0024442474
17. Yang W., Xiao J., Yang Z., Ji L., Jia W., Weng J., Lu J., Shan Z., Liu J., Tian H., Ji Q., Zhu D., Ge J., Lin L., Chen L., Guo X., Zhao Z., Li Q., Zhou Z., Shan G., He J., Serum lipids and lipoproteins in Chinese men and women. Circulation 2012 125 18 2212 2221 2-s2.0-84860762054 10.1161/CIRCULATIONAHA.111. 065904
18. Farzadfar F., Finucane M. M., Danaei G., Pelizzari P. M., Cowan M. J., Paciorek C. J., Singh G. M., Lin J. K., Stevens G. A., Riley L. M., Ezzati M., National, regional, and global trends in serum total cholesterol since 1980: systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3 · 0 million participants. The Lancet 2011 377 9765 578 586 2-s2.0-79951550993 10.1016/S0140-6736(10)62038-7
19. Yang G., Kong L., Zhao W., Wan X., Zhai Y., Chen L. C., Koplan J. P., Emergence of chronic non-communicable diseases in China. The Lancet 2008 372 9650 1697 1705 2-s2.0-55149106330 10.1016/S0140-6736(08)61366-5
20. Ding D., Qiu J., Li X., Xia M., Li Z., Su D., Wang Y., Zhang Y., Zhang J., Lv X., Xiao Y., Hu G., Ling W., Hyperglycemia and mortality among patients with coronary artery disease. Diabetes Care 2014 37 2 546 554 10.2337/dc13-1387
21. Gibbons R. J., Chatterjee K., Daley J., Douglas J. S., Fihn S. D., Gardin J. M., Grunwald M. A., Levy D., Lytle B. W., O'Rourke R. A., Schafer W. P., Williams S. V., Ritchie J. L., Eagle K. A., Gardner T. J., Garson A. J., Russell R. O., Ryan T. J., Smith S.C. J., ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: executive summary and recommendations: a report of the American college of cardiology/American heart association task force on practice guidelines (committee on management of patients with chronic stable angina). Circulation 1999 99 21 2829 2848 2-s2.0-0033152353
22. Braunwald E., Antman E. M., Beasley J. W., Califf R. M., Cheitlin M. D., Hochman J. S., Jones R. H., Kereiakes D., Kupersmith J., Levin T. N., Pepine C. J., Schaeffer J. W., Smith E. E. III, Steward D. E., Theroux P., Gibbons R. J., Alpert J. S., Eagle K. A., Faxon D. P., Fuster V., Gardner T. J., Gregoratos G., Russell R. O., Smith S.C. J., ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: executive summary and recommendations: a report of the American college of cardiology/American heart association task force on practice guidelines (committee on the management of patients with unstable angina). Circulation 2000 102 10 1193 1209 2-s2.0-0034609537
23. Zhang B., Wang P., Chen C. G., He Q., Zhuo S., Chen Y., Su Y., Validation of an FFQ to estimate the intake of fatty acids using erythrocyte membrane fatty acids and multiple 3d dietary records. Public Health Nutrition 2010 13 10 1546 1552 2-s2.0-77957240147 10.1017/S1368980009992849
24. Kolonel L. N., Henderson B. E., Hankin J. H., Nomura A. M. Y., Wilkens L. R., Pike M. C., Stram D. O., Monroe K. R., Earle M. E., Nagamine F. S., A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. The American Journal of Epidemiology 2000 151 4 346 357 2-s2.0-18844474648
25. The World Health Organization MONICA project (monitoring trends and determinants in cardiovascular disease): a major international collaboration. Journal of Clinical Epidemiology 1988 41 2 105 114 2-s2.0-0023866516
26. Levey A. S., Coresh J., Greene T., Stevens L. A., Zhang Y., Hendriksen S., Kusek J. W., Van Lente F., Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Annals of Internal Medicine 2006 145 4 247 254 2-s2.0-33747120659
27. Di Angelantonio E., Gao P., Pennells L., Kaptoge S., Caslake M., Thompson A., Butterworth A. S., Sarwar N., Wormser D., Saleheen D., Ballantyne C. M., Psaty B. M., Sundström J., Ridker P. M., Nagel D., Gillum R. F., Ford I., Ducimetiere P., Kiechl S., Koenig W., Dullaart R. P. F., Assmann G., D'Agostino R. B. Sr., Dagenais G. R., Cooper J. A., Kromhout D., Onat A., Tipping R., Gómez-de-la-Cámara A., Rosengren A., Sutherland S. E., Gallacher J., Fowkes F. G. R., Casiglia E., Hofman A., Salomaa V., Barrett-Connor E., Clarke R., Brunner E., Jukema J. W., Simons L. A., Sandhu M., Wareham N. J., Khaw K., Kauhanen J., Salonen J. T., Howard W. J., Nordestgaard B. G., Wood A. M., Thompson S. G., Boekholdt S. M., Sattar N., Packard C., Gudnason V., Danesh J., Lipid-related markers and cardiovascular disease prediction. The Journal of the American Medical Association 2012 307 23 2499 2506 2-s2.0-84862502750 10.1001/jama.2012.6571
28. Di Angelantonio E., Sarwar N., Perry P., Kaptoge S., Ray K. K., Thompson A., Wood A. M., Lewington S., Sattar N., Packard C. J., Collins R., Thompson S. G., Danesh J., Major lipids, apolipoproteins, and risk of vascular disease. The Journal of the American Medical Association 2009 302 18 1993 2000 2-s2.0-70450081001 10.1001/jama.2009.1619
29. Barter P., Gotto A. M., LaRosa J. C., Maroni J., Szarek M., Grundy S. M., Kastelein J. J. P., Bittner V., Fruchart J., HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. The New England Journal of Medicine 2007 357 13 1301 1310 2-s2.0-34748887666 10.1056/NEJMoa064278
30. Chapman M. J., Assmann G., Fruchart J. C., Shepherd J., Sirtori C., Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid-a position paper developed by the European consensus panel on HDL-C. Current Medical Research and Opinion 2004 20 8 1253 1268 2-s2.0-4344665253
31. Singh I. M., Shishehbor M. H., Ansell B. J., High-density lipoprotein as a therapeutic target: a systematic review. The Journal of the American Medical Association 2007 298 7 786 798 2-s2.0-34547858847 10.1001/jama.298.7.786
32. Duffy D., Rader D. J., Update on strategies to increase HDL quantity and function. Nature Reviews Cardiology 2009 6 7 455 463 2-s2.0-69849109122 10.1038/nrcardio.2009.94
33. Angeloni E., Paneni F., Landmesser U., Benedetto U., Melina G., Lüscher T. F., Volpe M., Sinatra R., Cosentino F., Lack of protective role of HDL-C in patients with coronary artery disease undergoing elective coronary artery bypass grafting. European Heart Journal 2013 34 46 3557 3562 10.1093/eurheartj/eht163
34. Besler C., Lüscher T. F., Landmesser U., Molecular mechanisms of vascular effects of High-density lipoprotein: alterations in cardiovascular disease. EMBO Molecular Medicine 2012 4 4 251 268 2-s2.0-84859384527 10.1002/emmm.201200224
35. Mineo C., Deguchi H., Griffin J. H., Shaul P. W., Endothelial and antithrombotic actions of HDL. Circulation Research 2006 98 11 1352 1364 2-s2.0-33745369351 10.1161/01.RES.0000225982.01988.93
36. Sorrentino S. A., Besler C., Rohrer L., Meyer M., Heinrich K., Bahlmann F. H., Mueller M., Horváth T., Doerries C., Heinemann M., Flemmer S., Markowski A., Manes C., Bahr M. J., Haller H., Von Eckardstein A., Drexler H., Landmesser U., Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation 2010 121 1 110 122 2-s2.0-74549172922 10.1161/CIRCULATIONAHA.108.836346
37. Schwartz G. G., Olsson A. G., Abt M., Ballantyne C. M., Barter P. J., Brumm J., Chaitman B. R., Holme I. M., Kallend D., Leiter L. A., Leitersdorf E., McMurray J. J. V., Mundl H., Nicholls S. J., Shah P. K., Tardif J., Wright R. S., Effects of dalcetrapib in patients with a recent acute coronary syndrome. The New England Journal of Medicine 2012 367 22 2089 2099 2-s2.0-84870045994 10.1056/NEJMoa1206797
38. Lüscher T. F., Taddei S., Kaski J. C., Jukema J. W., Kallend D., Münzel T., Kastelein J. J. P., Deanfield J. E., Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. European Heart Journal 2012 33 7 857 865 2-s2.0-84859517252 10.1093/eurheartj/ehs019
39. Moss A. J., Goldstein R. E., Marder V. J., Sparks C. E., Oakes D., Greenberg H., Weiss H. J., Zareba W., Brown M. W., Liang C., Lichstein E., Little W. C., Gillespie J. A., van Voorhees L., Krone R. J., Bodenheimer M. M., Hochman J., Dwyer E. M. Jr., Arora R., Marcus F. I., Watelet L. F. M., Case R. B., Thrombogenic factors and recurrent coronary events. Circulation 1999 99 19 2517 2522 2-s2.0-0033580591
40. Lu Q., Tian G., Zhang Y., Lu M., Lin X., Ma A., Low HDL-C predicts risk and PCI outcomes in the Han Chinese population. Atherosclerosis 2013 226 1 193 197 2-s2.0-84871368704 10.1016/j.atherosclerosis.2012.09.011
41. Olsson A. G., Schwartz G. G., Szarek M., Sasiela W. J., Ezekowitz M. D., Ganz P., Oliver M. F., Waters D., Zeiher A., High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. European Heart Journal 2005 26 9 890 896 2-s2.0-18744373337 10.1093/eurheartj/ehi186
42. Parish S., Offer A., Clarke R., Hopewell J. C., Hill M. R., Otvos J. D., Armitage J., Collins R., Lipids and lipoproteins and risk of different vascular events in the MRC/BHF heart protection study. Circulation 2012 125 20 2469 2478 2-s2.0-84861312926 10.1161/CIRCULATIONAHA.111.073684
43. Simes R. J., Marschner I. C., Hunt D., Colquhoun D., Sullivan D., Stewart R. A. H., Hague W., Keech A., Thompson P., White H., Shaw J., Tonkin A., Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation 2002 105 10 1162 1169 2-s2.0-0037066048 10.1161/hc1002.105136